Medical devices

In 2026, the U.S. medical device manufacturing market is strong but unforgiving, with growth concentrated in high-acuity cardiovascular, neuromodulation, and minimally invasive technologies while hospitals push suppliers harder on total cost, outcomes, and uptime.

MD&M West (Anaheim, February 3–5, 2026) remains one of the biggest “deal-floor” events for OEMs and contract manufacturers across design, plastics, automation, and medtech production scale-up.

HIMSS (Las Vegas, March 9–12, 2026) is where device manufacturers increasingly compete on interoperability, cybersecurity, and data workflows—not just hardware specs.

AdvaMed’s The MedTech Conference (Boston, October 18–21, 2026) is a major anchor for policy, reimbursement, and commercial strategy discussions that directly affect device adoption timelines.

M&A momentum rebounded in 2025 and is carrying into 2026 as buyers pursue “capability buys” in faster-growth categories rather than just adding capacity.

A headline deal shaping 2026 is Boston Scientific’s planned acquisition of Penumbra (about $14.5B), underscoring how valuable stroke and thrombectomy platforms have become.

Boston Scientific’s agreement to acquire Valencia Technologies highlights the continued push into implantable neuromodulation for bladder dysfunction (eCoin implantable tibial nerve stimulation).

Stryker’s acquisition of Inari Medical (announced at about $4.9B) signals the continued premium on peripheral vascular and venous thromboembolism device portfolios.

Another big “platform reshuffle” is BD’s plan to divest its biosciences and diagnostic solutions unit via a combination with Waters, showing how companies are refocusing portfolios and funding core medtech priorities.

New-product competition in 2026 is especially intense in pulsed-field ablation for atrial fibrillation, but safety and real-world outcomes can quickly change commercial trajectories.

J&J pausing U.S. sales of its Varipulse device after reports of neurovascular events is a clear reminder that post-launch surveillance and clinician confidence can matter as much as FDA approval.

On the legal front, antitrust scrutiny is real in medtech, with the FTC moving to block Edwards Lifesciences’ acquisition of JenaValve and a court granting a preliminary injunction in January 2026.

Product liability risk remains a constant background pressure, and private-equity ownership plus bankruptcy strategy has become a hot-button topic after the Exactech implant recall and subsequent bankruptcy dynamics.

Tariffs are still a sourcing and pricing variable, with USTR’s Section 301 modifications covering strategic-sector products and some increases staged into 2025–2026 timelines that can hit certain medical product categories.

Regulatory compliance tightens in 2026 because FDA’s Quality Management System Regulation (QMSR) becomes effective February 2, 2026, changing what inspectors expect and aligning more closely with ISO 13485 concepts.

Warehouse and distribution excellence is now a sales advantage because QMS discipline increasingly demands clean traceability, controlled handling, and fast, documented containment when complaints or field actions arise.

UDI-driven operations are becoming table stakes, since FDA’s UDI system is designed to identify devices through distribution to patient use, and labeling rules require UDIs on device labels under many circumstances.

Best-practice medtech warehouses in 2026 typically separate quarantine/returns from sellable inventory, enforce lot/serial scanning at receipt and pick, and run cycle counting to avoid “phantom stock” that triggers backorders during tenders and conversions.

Most U.S. customers ultimately sit in the hospital and health-system ecosystem (over 6,000 hospitals nationally), and contracting influence concentrates through large GPOs with major hubs like Vizient (Irving, TX), Premier (Charlotte, NC), and HealthTrust (Nashville, TN).

A common deal-closing mistake is treating clinical evidence, regulatory paperwork, and quality documentation as “later steps,” because hospital value-analysis teams and GPOs increasingly screen those items before the first serious sourcing conversation.

Another business-killing habit is ignoring traceability and distribution readiness (UDI scanning, recall playbooks, complaint-to-lot linkage, and clean returns handling)